Lilly expected FDA clearance for orforglipron by March 2026; the pill is now sold as Foundayo

Eli Lilly said on Nov. 6, 2025 that it expected the FDA to approve its experimental oral obesity drug, orforglipron, by March 2026 ^[1]. The forecast came from Lilly's chief executive, who spoke on a Thursday ^[1].

Orforglipron is a pill. At the time of that announcement it was still experimental, meaning it was not cleared for sale in the United States ^[1]. The November 2025 update did not include the results of Lilly's clinical trials, a list price, an insurance coverage plan or a launch date, and it did not say how far along the FDA's review was ^[1].

The drug has since reached the market. Lilly now sells it as Foundayo, and on Sept. 14, 2026 the company said Foundayo had captured more than 30% of new US patients starting oral weight-loss drugs ^[1]. That number describes the drug's share of new patients on oral weight-loss medicines specifically. It does not cover the larger market for obesity drugs, which includes injected products, and it does not say how many patients in total take the drug ^[1].

Foundayo is orforglipron. It is not semaglutide, the molecule in Ozempic, Wegovy and Rybelsus, and it is not tirzepatide, the molecule in Mounjaro and Zepbound. The exact date the FDA cleared the drug has not been reported.

Why it matters for patients

The practical difference with an oral drug is the route: a pill is swallowed rather than injected. For people who dislike needles, have trouble storing injectable medicines, or simply prefer a tablet, a pill option changes what taking a GLP-1 medicine involves day to day.

The 30% figure is a signal about how quickly the pill has been adopted by new patients and their prescribers, but it says nothing about how much weight people lost on it or how it compares with injected medicines. No head-to-head comparison with semaglutide or tirzepatide appears in the company's updates ^[1].

Cost is another open question. Neither the November 2025 announcement nor the September 2026 update included a list price or details of insurance coverage ^[1]. What a patient pays typically depends on their plan, and that information has not been disclosed.

Nothing in these updates speaks to switching from an injected medicine to the pill, and none of them report how patients who switch would be monitored. Anyone weighing a change in treatment is making a medical decision that depends on their own history, and the announcements do not address it.

What happens next

• March 2026: the target date Lilly gave for FDA approval of orforglipron ^[1].
• Sept. 14, 2026: Lilly said Foundayo had taken more than 30% of new US patients on oral weight-loss drugs ^[1].
• Not yet reported: clinical trial results, list price, insurance coverage, and the exact date of the FDA's decision ^[1].

Lilly has not said whether it plans to seek approval for other uses of orforglipron, and it has not disclosed how the drug is priced against injected options ^[1]. Those details would shape what the pill means for patients deciding between a tablet and a shot.